Cancer diagnostic firm Caris Life Sciences on Monday raised the proposed price range for its New York initial public offering, targeting a valuation of up to $5.67 billion and indicating a strong ...

Private equity-backed Jefferson Capital said on Friday it was targeting a valuation of up to $1.1 billion in its U.S. initial ...

Metsera showed 0% earnings growth in its most recent report, while sales growth came in at 0%. Metsera earns the No. 177 rank among its peers in the Medical-Biomed/Biotech industr ...

(Corrects paragraph 3 to say 36 days, not 36 weeks) (Reuters) -Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose ...

Following a flurry of activity in early 2025, the IPO scene has cooled in the wake of President Trump’s economic tremors.